Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning ways. At its Capital Markets Day on 21 September, Novo's strategy was headlined by an ambition to launch more than five multi-blockbusters by 2030. This is accompanied by a target to deliver more than DKr150bn ($23bn) in sales. The moves are part of Novo's strategy to showcase to investors what its roadmap looks like beyond semaglutide. The injectable versions of the drug, branded under Wegovy and Ozempic, generated around $7.8bn in global sales in Q2. However, the company is lagging Eli Lilly in the cardiometabolic space.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。